BUZZ-BeiGene's H-shares hit 4-week peak on products inclusion in China drug catalog** H-shares of BeiGene 6160.HK jump 4.9% to HK$128.2, highest since Oct. 30
** Stock set for third consecutive session of gains
** Shanghai stock 688235.SS of the Chinese oncology treatments developer rises 2.5% to 180.39 yuan
** BeiGene says few of its oncology products will be included in the National Medical Insurance Drug Catalog effective Jan. 1, 2025
** Adds inclusion will benefit marketing and sales of the products
** YTD, Hong Kong stock gains 11% vs Shanghai shares' 30.4% rise
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments